TORONTO--(Marketwire - February 02, 2012) - SenoSENSE Medical Systems Inc., a medical device company engaged in the development of innovative technologies targeted to reducing the impact of breast cancer in younger women, announced today that it has received an Investigational Testing Approval (ITA) from Health Canada. Receipt of the ITA enables the company to initiate clinical testing of SenoSENSE's proprietary Densitrode technology which is planned to begin in February 2012 at Timmins and District Hospital. Dr. Karina Bukhanov, Breast Radiologist with Mount Sinai Hospital Marvelle Koffler Breast Centre and Gattuso Rapid Diagnosis Clinic at Princess Margaret Hospital is the principal investigator for the initial studies.
"The receipt of Investigation Testing Approval for the Densitrode™ beast density sensor represents the first important step in advancing an exciting new technology that we believe offers great promise to identify younger women who are at increased risk of breast cancer, enable proactive intervention to reduce their risk and initiate earlier surveillance to identify cancer at an earlier and more treatable stage," commented Joel Ironstone, President and Chief Executive Officer of SenoSENSE Medical Systems.
About SenoSENSE Medical
SenoSENSE Medical Systems is a Toronto, Ontario-based early stage medical device company developing technology that enables personalized assessment of breast cancer risk in younger women. The company's first product, the Electrical Breast Densitometer, employs proprietary Densitrode technology to assess breast density in combination with other well-accepted breast cancer risk factors. Breast density has emerged as one of the most important determinants of breast cancer risk. A woman with high breast density has 4-6 times higher risk of developing breast cancer than a woman with fatty, low density tissue. Breast cancer is the most prevalent cause of death in women under the age of 50.